Refine
Year of publication
Document Type
- Article (73) (remove)
Has Fulltext
- yes (73)
Is part of the Bibliography
- no (73)
Keywords
- COVID-19 (4)
- SARS-CoV-2 (3)
- risk factors (3)
- ACLF (2)
- Biomarkers (2)
- Immunology (2)
- Non-small cell lung cancer (2)
- Portal hypertension (2)
- acute myeloid leukemia (2)
- acute-on-chronic liver failure (2)
- cirrhosis (2)
- inflammation (2)
- portal hypertension (2)
- 32D progenitor cells (1)
- 3years (1)
- ABCB1 (1)
- ABCC1 (1)
- ADGRE1 (1)
- ALK-rearranged NSCLC (1)
- Acute Myeloid Leukemia (AML) (1)
- Acute kidney injury (1)
- Advanced stage (1)
- Alternative oxidase (1)
- Angiogenesis (1)
- Angiography (1)
- Ankylosierende Spondylitis (1)
- Ankylosing spondylitis (1)
- Axial spondyloarthritis (1)
- Axiale Spondyloarthritis (1)
- BCOR (1)
- BCORL1 (1)
- BI1361849 (1)
- BRVO (1)
- Blood (1)
- Blood loss (1)
- Blood plasma (1)
- Brain tumor (1)
- CAKUT (1)
- CBA (1)
- CLIF-C ACLF score (1)
- CLIF-C ACLF-R score (1)
- COPD (1)
- COVID (1)
- CV9202 (1)
- CVD biomarker (1)
- Cancer (1)
- Cardiology (1)
- Care gaps (1)
- Cirrhosis (1)
- Clinical trial (1)
- Cohort studies (1)
- Colloids (1)
- Complicated stage (1)
- DME (1)
- Devic disease (1)
- Devic syndrome (1)
- Diabetes (1)
- Drug resistance (1)
- Drug targets (1)
- EMR1 (1)
- EWSR1 (1)
- Emphysema (1)
- Everolimus (1)
- Extended donor criteria (1)
- F4/80 (1)
- FOXO3a (1)
- G3BP (1)
- Gene fusion (1)
- Genetic testing (1)
- Genetics (1)
- Germany (1)
- Graft function (1)
- Graft survival (1)
- HES (1)
- Haematocrit (1)
- Hashimoto’s thyroiditis (1)
- Health care (1)
- Health information (1)
- Health-seeking behaviour (1)
- Heat shock protein 27 (1)
- Helpline (1)
- Hydroxyethyl starch (1)
- Hypofractionated radiotherapy (1)
- IL-6 (1)
- ILUVIEN (1)
- Immunogenetics (1)
- Immunomonitoring (1)
- JAK2V617F (1)
- K3EDTA plasma sampling (1)
- Kidney transplantation (1)
- LEOSS (1)
- Lipidomics (1)
- Liver cirrhosis (1)
- Liver transplantation (1)
- Ltbp4 (1)
- MCP (1)
- MN1 (1)
- MR-proADM (1)
- Machine learning (1)
- Marginal grafts (1)
- Mean erythrocyte volume (1)
- Medication Appropriateness Index (1)
- Metabolic models (1)
- Metabolic vulnerabilities (1)
- Metabolomics (1)
- Mitochondria (1)
- Mitochondrial disease (1)
- Molecular diagnostic testing (1)
- Molecular medicine (1)
- Mortality (1)
- NAFL (1)
- NAFLD (1)
- NASH (1)
- NMO-IgG (1)
- Nephrons (1)
- Neuroepithelial (1)
- Neuromyelitis optica (1)
- Neurooncology (1)
- Nrf2 (1)
- Number of platelets (1)
- Oncology (1)
- Organ rinse (1)
- Organ shortage (1)
- PATZ1 (1)
- PTDM (1)
- Pdgfrβ (1)
- Pediatric (1)
- Periodontitis grades B and C (1)
- Polo-like kinase 3 (1)
- Portal veins (1)
- Post-transplant (1)
- Pre-analytics (1)
- Predictive model (1)
- Primary prophylaxis (1)
- Proteins (1)
- Psychiatric disorders (1)
- Quality of care (1)
- Quality standards (1)
- Qualitätsstandards (1)
- ROS (1)
- Radical nephrectomy (1)
- Rare diseases (1)
- Registries (1)
- Renal cancer (1)
- Renal system (1)
- Respiratory chain (1)
- Retro-IDEAL (1)
- Rho GTPases (1)
- SD-OCT (1)
- SLC20A1 (1)
- SOFA (1)
- SPSS (1)
- Sampling protocol (1)
- Sepsis (1)
- Septic shock (1)
- Spontaneous bacterial peritonitis (1)
- Steroid (1)
- Surgical and invasive medical procedures (1)
- Surgical oncology (1)
- Survival analysis (1)
- TGR(mREN2)27 (1)
- TOR inhibitor (1)
- TP53 mutation status (1)
- Tacrolimus (1)
- Telemedicine (1)
- Tgfβ (1)
- Trauma (1)
- VEGF (1)
- Versorgungslücken (1)
- Versorgungsqualität (1)
- Volume therapy (1)
- Western diet (1)
- White blood cells (1)
- YM155 (1)
- accident (1)
- acute decompensation (1)
- acute-on-chronic liver failure (ACLF) (1)
- adhesion (1)
- advanced care planning (1)
- aftercare structures (1)
- aging (1)
- anal carcinoma (1)
- anticonvulsants (1)
- aquaporin-4 (AQP4) antibody (1)
- bladder exstrophy-epispadias complex (1)
- bleeding (1)
- cancer (1)
- caspase-8 (1)
- cerebrospinal fluid (1)
- chemoradiotherapy (1)
- chronic kidney disease (1)
- chronic myeloid leukemia (1)
- clinical features (1)
- cloacal malformation (1)
- comorbidities (1)
- computed tomography (1)
- computer-assisted drug therapy (1)
- consensus (1)
- critically ill patients (1)
- cytarabine dose (1)
- day clinic (1)
- decompensated liver cirrhosis (1)
- differentiated thyroid carcinoma (1)
- drug resistance (1)
- dysbiosis (1)
- elderly (1)
- epidemiology (1)
- epilepsy (1)
- epileptic encephalopathies (1)
- essential thrombocythemia (ET) (1)
- functional genetics (1)
- glycobiology (1)
- glycoconjugate (1)
- health information exchange (1)
- hepatic encephalopathy (1)
- homing (1)
- hospital admission (1)
- immunity (1)
- infectious disease (1)
- injury (1)
- kidney formation (1)
- lasso regression (1)
- lethal toxin (1)
- levetiracetam (1)
- liver (1)
- liver fibrosis (1)
- liver transplantation (1)
- liver transplantation center (1)
- local control (1)
- lockdown (1)
- long-term outcome (1)
- longitudinally extensive transverse myelitis (1)
- loss-of-function (1)
- mRNA active cancer immunotherapy (1)
- macrophage (1)
- magnetic resonance imaging (1)
- male (1)
- mechanical ventilation (1)
- medication reconciliation (1)
- metabolic reprogramming (1)
- metabolic syndromes (1)
- microbiome (1)
- microdosing (1)
- migration (1)
- molecular modeling (1)
- monocyte chemotactic protein 1 (MCP-1) (1)
- mortality (1)
- multimodal complex treatment (1)
- multimorbidity (1)
- multiple chronic conditions (1)
- myeloproliferative neoplasms (MPN) (1)
- networks (1)
- neuroblastoma (1)
- neurodegeneration (1)
- neurological manifestations (1)
- neutralizing antibodies (1)
- nomogram (1)
- pediatric intensive care (1)
- peri-implantitis (1)
- polycythemia vera (PV) (1)
- polypharmacy (1)
- portosystemic shunt (1)
- post-liver transplantation management (1)
- primary myelofibrosis (PMF) (1)
- proteomics (1)
- pulmonary failure (1)
- qualitative research (1)
- quality control (1)
- rare diseases (1)
- recurrent optic neuritis (1)
- renal dysfunction (1)
- respiratory failure (1)
- retrovirus (1)
- risk factor progression (1)
- risk stratification (1)
- seizure (1)
- sequential ALK-inhibitor therapy (1)
- sialic acid (1)
- sirtuin1 (1)
- spike protein (1)
- spontaneous portosystemic shunt (1)
- survival (1)
- survivin (1)
- thromboembolism (1)
- thrombosis (1)
- toxin B (1)
- transjugular intrahepatic portosystemic shunt (TIPS) (1)
- trauma (1)
- tyrosine kinase inhibitors. (1)
- urinary tract development (1)
- variants of concern (1)
- vitamin D (1)
- vitamin D receptor (1)
- vitreous samples (1)
- zebrafish development (1)
Institute
- Medizin (73) (remove)
Children’s and adolescents’ lives drastically changed during COVID lockdowns worldwide. To compare accident- and injury-related admissions to pediatric intensive care units (PICU) during the first German COVID lockdown with previous years, we conducted a retrospective multicenter study among 37 PICUs (21.5% of German PICU capacities). A total of 1444 admissions after accidents or injuries during the first lockdown period and matched periods of 2017–2019 were reported and standardized morbidity ratios (SMR) were calculated. Total PICU admissions due to accidents/injuries declined from an average of 366 to 346 (SMR 0.95 (CI 0.85–1.05)). Admissions with trauma increased from 196 to 212 (1.07 (0.93–1.23). Traffic accidents and school/kindergarten accidents decreased (0.77 (0.57–1.02 and 0.26 (0.05–0.75)), whereas household and leisure accidents increased (1.33 (1.06–1.66) and 1.34 (1.06–1.67)). Less neurosurgeries and more visceral surgeries were performed (0.69 (0.38–1.16) and 2.09 (1.19–3.39)). Non-accidental non-suicidal injuries declined (0.73 (0.42–1.17)). Suicide attempts increased in adolescent boys (1.38 (0.51–3.02)), but decreased in adolescent girls (0.56 (0.32–0.79)). In summary, changed trauma mechanisms entailed different surgeries compared to previous years. We found no evidence for an increase in child abuse cases requiring intensive care. The increase in suicide attempts among boys demands investigation.
Background: Trauma may be associated with significant to life-threatening blood loss, which in turn may increase the risk of complications and death, particularly in the absence of adequate treatment. Hydroxyethyl starch (HES) solutions are used for volume therapy to treat hypovolemia due to acute blood loss to maintain or re-establish hemodynamic stability with the ultimate goal to avoid organ hypoperfusion and cardiovascular collapse. The current study compares a 6% HES 130 solution (Volulyte 6%) versus an electrolyte solution (Ionolyte) for volume replacement therapy in adult patients with traumatic injuries, as requested by the European Medicines Agency to gain more insights into the safety and efficacy of HES in the setting of trauma care.
Methods: TETHYS is a pragmatic, prospective, randomized, controlled, double-blind, multicenter, multinational trial performed in two parallel groups. Eligible consenting adults ≥ 18 years, with an estimated blood loss of ≥ 500 ml, and in whom initial surgery is deemed necessary within 24 h after blunt or penetrating trauma, will be randomized to receive intravenous treatment at an individualized dose with either a 6% HES 130, or an electrolyte solution, for a maximum of 24 h or until reaching the maximum daily dose of 30 ml/kg body weight, whatever occurs first. Sample size is estimated as 175 patients per group, 350 patients total (α = 0.025 one-tailed, power 1–β = 0.8). Composite primary endpoint evaluated in an exploratory manner will be 90-day mortality and 90-day renal failure, defined as AKIN stage ≥ 2, RIFLE injury/failure stage, or use of renal replacement therapy (RRT) during the first 3 months. Secondary efficacy and safety endpoints are fluid administration and balance, changes in vital signs and hemodynamic status, changes in laboratory parameters including renal function, coagulation, and inflammation biomarkers, incidence of adverse events during treatment period, hospital, and intensive care unit (ICU) length of stay, fitness for ICU or hospital discharge, and duration of mechanical ventilation and/or RRT.
Discussion: This pragmatic study will increase the evidence on safety and efficacy of 6% HES 130 for treatment of hypovolemia secondary to acute blood loss in trauma patients.
Trial registration:Registered in EudraCT, No.: 2016-002176-27 (21 April 2017) and ClinicalTrials.gov, ID: NCT03338218 (09 November 2017).
Large-scale molecular profiling studies in recent years have shown that central nervous system (CNS) tumors display a much greater heterogeneity in terms of molecularly distinct entities, cellular origins and genetic drivers than anticipated from histological assessment. DNA methylation profiling has emerged as a useful tool for robust tumor classification, providing new insights into these heterogeneous molecular classes. This is particularly true for rare CNS tumors with a broad morphological spectrum, which are not possible to assign as separate entities based on histological similarity alone. Here, we describe a molecularly distinct subset of predominantly pediatric CNS neoplasms (n = 60) that harbor PATZ1 fusions. The original histological diagnoses of these tumors covered a wide spectrum of tumor types and malignancy grades. While the single most common diagnosis was glioblastoma (GBM), clinical data of the PATZ1-fused tumors showed a better prognosis than typical GBM, despite frequent relapses. RNA sequencing revealed recurrent MN1:PATZ1 or EWSR1:PATZ1 fusions related to (often extensive) copy number variations on chromosome 22, where PATZ1 and the two fusion partners are located. These fusions have individually been reported in a number of glial/glioneuronal tumors, as well as extracranial sarcomas. We show here that they are more common than previously acknowledged, and together define a biologically distinct CNS tumor type with high expression of neural development markers such as PAX2, GATA2 and IGF2. Drug screening performed on the MN1:PATZ1 fusion-bearing KS-1 brain tumor cell line revealed preliminary candidates for further study. In summary, PATZ1 fusions define a molecular class of histologically polyphenotypic neuroepithelial tumors, which show an intermediate prognosis under current treatment regimens.
Background: The diagnostic and pathophysiological relevance of antibodies to aquaporin-4 (AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD) has been intensively studied. However, little is known so far about the clinical impact of AQP4-Ab seropositivity.
Objective: To analyse systematically the clinical and paraclinical features associated with NMO spectrum disorders in Caucasians in a stratified fashion according to the patients' AQP4-Ab serostatus.
Methods: Retrospective study of 175 Caucasian patients (AQP4-Ab positive in 78.3%).
Results: Seropositive patients were found to be predominantly female (p < 0.0003), to more often have signs of co-existing autoimmunity (p < 0.00001), and to experience more severe clinical attacks. A visual acuity of ≤ 0.1 during acute optic neuritis (ON) attacks was more frequent among seropositives (p < 0.002). Similarly, motor symptoms were more common in seropositive patients, the median Medical Research Council scale (MRC) grade worse, and MRC grades ≤ 2 more frequent, in particular if patients met the 2006 revised criteria (p < 0.005, p < 0.006 and p < 0.01, respectively), the total spinal cord lesion load was higher (p < 0.006), and lesions ≥ 6 vertebral segments as well as entire spinal cord involvement more frequent (p < 0.003 and p < 0.043). By contrast, bilateral ON at onset was more common in seronegatives (p < 0.007), as was simultaneous ON and myelitis (p < 0.001); accordingly, the time to diagnosis of NMO was shorter in the seronegative group (p < 0.029). The course of disease was more often monophasic in seronegatives (p < 0.008). Seropositives and seronegatives did not differ significantly with regard to age at onset, time to relapse, annualized relapse rates, outcome from relapse (complete, partial, no recovery), annualized EDSS increase, mortality rate, supratentorial brain lesions, brainstem lesions, history of carcinoma, frequency of preceding infections, oligoclonal bands, or CSF pleocytosis. Both the time to relapse and the time to diagnosis was longer if the disease started with ON (p < 0.002 and p < 0.013). Motor symptoms or tetraparesis at first myelitis and > 1 myelitis attacks in the first year were identified as possible predictors of a worse outcome.
Conclusion: This study provides an overview of the clinical and paraclinical features of NMOSD in Caucasians and demonstrates a number of distinct disease characteristics in seropositive and seronegative patients
Simple Summary: In patients with myeloproliferative neoplasms (MPN) and in patients with kidney dysfunction, a higher rate of thrombosis has been reported compared with the general population. Furthermore, MPN patients are more prone to develop kidney dysfunction. In our study, we assessed the importance of specific risk factors for kidney dysfunction and thrombosis in MPN patients. We found that the rate of thrombosis is correlated with the degree of kidney dysfunction, especially in myelofibrosis. Significant associations for kidney dysfunction included arterial hypertension, MPN treatment, and increased inflammation, and those for thrombosis comprised arterial hypertension, non-excessive platelet counts, and antithrombotic therapy. The identified risk factor associations varied between MPN subtypes. Our data suggest that kidney dysfunction in MPN patients is associated with an increased risk of thrombosis, mandating closer monitoring, and, possibly, early thromboprophylaxis.
Abstract: Inflammation-induced thrombosis represents a severe complication in patients with myeloproliferative neoplasms (MPN) and in those with kidney dysfunction. Overlapping disease-specific attributes suggest common mechanisms involved in MPN pathogenesis, kidney dysfunction, and thrombosis. Data from 1420 patients with essential thrombocythemia (ET, 33.7%), polycythemia vera (PV, 38.5%), and myelofibrosis (MF, 27.9%) were extracted from the bioregistry of the German Study Group for MPN. The total cohort was subdivided according to the calculated estimated glomerular filtration rate (eGFR, (mL/min/1.73 m2)) into eGFR1 (≥90, 21%), eGFR2 (60–89, 56%), and eGFR3 (<60, 22%). A total of 29% of the patients had a history of thrombosis. A higher rate of thrombosis and longer MPN duration was observed in eGFR3 than in eGFR2 and eGFR1. Kidney dysfunction occurred earlier in ET than in PV or MF. Multiple logistic regression analysis identified arterial hypertension, MPN treatment, increased uric acid, and lactate dehydrogenase levels as risk factors for kidney dysfunction in MPN patients. Risk factors for thrombosis included arterial hypertension, non-excessive platelet counts, and antithrombotic therapy. The risk factors for kidney dysfunction and thrombosis varied between MPN subtypes. Physicians should be aware of the increased risk for kidney disease in MPN patients, which warrants closer monitoring and, possibly, early thromboprophylaxis.
Background: This study assessed the ability of mid-regional proadrenomedullin (MR-proADM) in comparison to conventional biomarkers (procalcitonin (PCT), lactate, C-reactive protein) and clinical scores to identify disease severity in patients with sepsis.
Methods: This is a secondary analysis of a randomised controlled trial in patients with severe sepsis or septic shock across 33 German intensive care units. The association between biomarkers and clinical scores with mortality was assessed by Cox regression analysis, area under the receiver operating characteristic and Kaplan-Meier curves. Patients were stratified into three severity groups (low, intermediate, high) for all biomarkers and scores based on cutoffs with either a 90% sensitivity or specificity.
Results: 1089 patients with a 28-day mortality rate of 26.9% were analysed. According to the Sepsis-3 definition, 41.2% and 58.8% fulfilled the criteria for sepsis and septic shock, with respective mortality rates of 20.0% and 32.1%. MR-proADM had the strongest association with mortality across all Sepsis-1 and Sepsis-3 subgroups and could facilitate a more accurate classification of low (e.g. MR-proADM vs. SOFA: N = 265 vs. 232; 9.8% vs. 13.8% mortality) and high (e.g. MR-proADM vs. SOFA: N = 161 vs. 155; 55.9% vs. 41.3% mortality) disease severity. Patients with decreasing PCT concentrations of either ≥ 20% (baseline to day 1) or ≥ 50% (baseline to day 4) but continuously high MR-proADM concentrations had a significantly increased mortality risk (HR (95% CI): 19.1 (8.0–45.9) and 43.1 (10.1–184.0)).
Conclusions: MR-proADM identifies disease severity and treatment response more accurately than established biomarkers and scores, adding additional information to facilitate rapid clinical decision-making and improve personalised sepsis treatment.
Background: Patients with liver cirrhosis have a highly elevated risk of developing bacterial infections that significantly decrease survival rates. One of the most relevant infections is spontaneous bacterial peritonitis (SBP). Recently, NOD2 germline variants were found to be potential predictors of the development of infectious complications and mortality in patients with cirrhosis. The aim of the INCA (Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver Cirrhosis and Ascites) trial is to investigate whether survival of this genetically defined high-risk group of patients with cirrhosis defined by the presence of NOD2 variants is improved by primary antibiotic prophylaxis of SBP.
Methods/Design: The INCA trial is a double-blind, placebo-controlled clinical trial with two parallel treatment arms (arm 1: norfloxacin 400 mg once daily; arm 2: placebo once daily; 12-month treatment and observational period). Balanced randomization of 186 eligible patients with stratification for the protein content of the ascites (<15 versus ≥15 g/L) and the study site is planned. In this multicenter national study, patients are recruited in at least 13 centers throughout Germany. The key inclusion criterion is the presence of a NOD2 risk variant in patients with decompensated liver cirrhosis. The most important exclusion criteria are current SBP or previous history of SBP and any long-term antibiotic prophylaxis. The primary endpoint is overall survival after 12 months of treatment. Secondary objectives are to evaluate whether the frequencies of SBP and other clinically relevant infections necessitating antibiotic treatment, as well as the total duration of unplanned hospitalization due to cirrhosis, differ in both study arms. Recruitment started in February 2014.
Discussion: Preventive strategies are required to avoid life-threatening infections in patients with liver cirrhosis, but unselected use of antibiotics can trigger resistant bacteria and worsen outcome. Thus, individualized approaches that direct intervention only to patients with the highest risk are urgently needed. This trial meets this need by suggesting stratified prevention based on genetic risk assessment. To our knowledge, the INCA trial is first in the field of hepatology aimed at rapidly transferring and validating information on individual genetic risk into clinical decision algorithms.
Trial registrations: German Clinical Trials Register DRKS00005616. Registered 22 January 2014. EU Clinical Trials Register EudraCT 2013-001626-26. Registered 26 January 2015.
Overconsumption of carbohydrates and lipids are well known to cause nonalcoholic fatty liver disease (NAFLD), while the role of nutritional protein intake is less clear. In Western diet, meat and other animal products are the main protein source, with varying concentrations of specific amino acids. Whether the amount or composition of protein intake is associated with a higher risk for disease severity has not yet been examined. In this study, we investigated associations of dietary components with histological disease activity by analyzing detailed 14‐day food records in a cohort of 61 patients with biopsy‐proven NAFLD. Furthermore, we used 16S ribosomal RNA gene sequencing to detect associations with different abundances of the gut microbiota with dietary patterns. Patients with definite nonalcoholic steatohepatitis (NAFLD activity score of 5‐8 on liver biopsy) had a significantly higher daily relative intake of protein compared with patients with a NAFLD activity score of 0‐4 (18.0% vs. 15.8% of daily protein‐based calories, P = 0.018). After adjustment for several potentially confounding factors, a higher protein intake (≥17.3% of daily protein‐based calories) remained associated with definite nonalcoholic steatohepatitis, with an odds ratio of 5.09 (95% confidence interval 1.22‐21.25, P = 0.026). This association was driven primarily by serine, glycine, arginine, proline, phenylalanine, and methionine. A higher protein intake correlated with a lower Bacteroides abundance and an altered abundance of several other bacterial taxa. Conclusion: A high protein intake was independently associated with more active and severe histological disease activity in patients with NAFLD. Further studies are needed to investigate the potential harmful role of dietary amino acids on NAFLD, with special attention to meat as their major source.
Latent transforming growth factor beta binding protein 4 (LTBP4) belongs to the fibrillin/LTBP family of proteins and plays an important role as a structural component of extracellular matrix (ECM) and local regulator of TGFβ signaling. We have previously reported that Ltbp4S knock out mice (Ltbp4S −/−) develop centrilobular emphysema reminiscent of late stage COPD, which could be partially rescued by inactivating the antioxidant protein Sestrin 2 (Sesn2). More recent studies showed that Sesn2 knock out mice upregulate Pdgfrβ-controlled alveolar maintenance programs that protect against cigarette smoke induced pulmonary emphysema. Based on this, we hypothesized that the emphysema of Ltbp4S −/− mice is primarily caused by defective Pdgfrβ signaling. Here we show that LTBP4 induces Pdgfrβ signaling by inhibiting the antioxidant Nrf2/Keap1 pathway in a TGFβ-dependent manner. Overall, our data identified Ltbp4 as a major player in lung remodeling and injury repair.
Introduction: The Retro-IDEAL (ILUVIEN Implant for chronic DiabEtic MAcuLar edema) study is a retrospective study designed to assess real-world outcomes achieved with the ILUVIEN® (0.19 mg fluocinolone acetonide (FAc)) in patients with chronic diabetic macular edema (DME) in clinical practices in Germany.
Methods: This study was conducted across 16 sites in Germany and involved 81 eyes (63 patients) with persistent or recurrent DME and a prior suboptimal response to a first-line intravitreal therapy (primarily anti-VEGF intravitreal therapies).
Results: Patients were followed-up for 30.8 ± 11.3 months (mean ± standard deviation) and had a mean age of 68.0 ± 10.4 years. Best-recorded visual acuity (BRVA) improved by +5.5 letters at month 9 (P ⩽ 0.005, n=56; from a baseline of 49 letters) and this was maintained through to month 30 (P ⩽ 0.05, n = 42). There was a concurrent improvement in central macular thickness with a reduction from 502 µm at baseline to 338 µm at year 1 (P ⩽ 0.0001, n = 43). This effect was sustained to year 3 (i.e. 318 µm; P ⩽ 0.0001, n = 29). Mean intraocular pressure (IOP) remained constant between baseline and year 3 with a peak change of 1.9 mm Hg occurring at year 1. Elevated IOP was observed in a similar percentage of patients prior to (22.2% of cases) and following (27.2%) treatment with the FAc implant. In the majority of cases, these elevations were managed effectively with IOP medications.
Conclusions: Despite substantial amounts of prior intravitreal treatments – primarily with anti–vascular endothelial growth factor (VEGF) drugs – this real-world study showed that sustained structural and functional improvements can last for up to 3 years with a single FAc implant.